Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
about
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyManagement of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French STherapy-related myeloid neoplasms: pathobiology and clinical characteristics[Neutropenia and sepsis].Growth factor use in medication-induced hematologic toxicity.Impact of acute hematological toxicity on treatment interruptions during cranio-spinal irradiation in medulloblastoma: a tertiary care institute experience.Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study.How we treat febrile neutropenia in patients receiving cancer chemotherapyPharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trialGranulocyte colony-stimulating factor use in a large British hospital: comparison with published experience.Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia.A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findingsManagement of febrile neutropaenia: ESMO Clinical Practice Guidelines.Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay.How to treat severe infections in critically ill neutropenic patients?Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study.Canadian supportive care recommendations for the management of neutropenia in patients with cancer.Supportive therapy in medical therapy of head and neck tumors.Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomesGranulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma.A Type II Arabinogalactan from Anoectochilus formosanus for G-CSF Production in Macrophages and Leukopenia Improvement in CT26-Bearing Mice Treated with 5-FluorouracilGranulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?Colony-stimulating factors for febrile neutropenia during cancer therapy.Supportive care in hemato-oncology: a review in light of the latest guidelines.Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials.Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology.Myeloid growth factors as anti-infective measures in children with leukemia and lymphoma.Immune response to Aspergillus fumigatus in compromised hosts: from bedside to bench.Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.
P2860
Q24241680-C0C932B1-5215-4FBB-925A-7B52E988EC92Q27320711-180A09E0-DCAB-4739-9DC7-465F4B171973Q28386366-05FD3DCC-B436-472A-B9F4-1DF233C0A0EAQ33409974-BA2E841E-EAEE-48A5-B202-8A474F41A740Q33417812-10B999EB-9A16-46BF-A6A8-1975A37A334BQ33442381-3FC1E45C-83D7-4721-9388-6AD69340E8EFQ33539387-41A05F72-FC2B-48B8-89AD-08A2E0DD408DQ33800526-4619A47C-33E6-41FB-B55C-506CCC264215Q33846201-B2254271-9E42-43C0-B81F-A6DADE05333CQ34013208-0E46FD9E-7818-43D6-A702-72FD27E26FA9Q34021672-1787B46E-F884-4666-A60C-54A9B557C134Q34374754-2D1134F3-249D-4BFE-A70D-71F47EAF3242Q34583481-27D73C08-346C-4171-B3AF-74D87D99FEC6Q34627796-440E906B-6ABC-4A5A-AFBE-BC9DD86C8BCAQ34678894-EC8C6B9B-BE95-4AD5-9931-B0A6E8811D01Q35054865-A39C8CF5-CCE3-4CF1-A711-D4C4636F529FQ35457899-D358ACE8-8C27-4579-99D0-C027BF9C18C3Q35753638-5F34F79B-A9A7-4FAB-8189-AE1316587EC5Q36485208-C243061C-E874-4702-8E7A-73E60795C4B6Q36529853-7605AC79-8315-4CDD-B117-6E7491F19ED7Q36677460-46351C79-F011-4113-9FF3-620631A93CC9Q36907218-D6D0EB8F-E4BC-46D0-9E58-F6C843C41C8BQ36936723-54A80441-785E-4E61-9D13-C1A8F63860F0Q37244091-7AF88574-D184-4E75-84F5-76C23A3738F5Q37354296-009403D6-3E23-4232-AA54-A910D379BC87Q37626772-3ED6F46C-65F5-407D-BEF6-78598466B7E2Q37702827-5F5EB9B3-66F7-4457-970A-1B45159D1FE3Q37766379-63F642B2-814C-4447-A97E-5232877E7CCFQ37788578-B9383496-F5A8-4571-B87E-D4834CDF6658Q37805910-21D085A2-C940-43AD-A34D-D1C51A3B40E4Q37810266-EB0F7666-BF87-44AC-A67A-8891CF0C7931Q37821488-B9E778AA-5DB0-48BE-B4AB-066F9C6CE870Q37831314-4FDDD75C-DF43-4C58-82BA-45DE808D6698Q37866758-150567E1-08D7-44C7-BE35-79BEB90A62C6Q37931905-779B738F-0C7F-4EA6-8C81-B454F935E1F4Q38006021-5AFBC1B4-EAFF-42AD-AAF6-8D03EC6D71F4Q38207933-8706B36E-194C-4B55-B7CD-B46F00333840Q38225700-0068D5AD-8D65-4BA0-870B-F7E7A08BFA31Q38246766-1D239043-882F-4351-ACC6-CDE6860A0F70Q38256944-97C1849A-B0A7-4482-8AA5-3FC12434B261
P2860
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Colony-stimulating factors for ...... randomized controlled trials.
@ast
Colony-stimulating factors for ...... randomized controlled trials.
@en
Colony-stimulating factors for ...... randomized controlled trials.
@nl
type
label
Colony-stimulating factors for ...... randomized controlled trials.
@ast
Colony-stimulating factors for ...... randomized controlled trials.
@en
Colony-stimulating factors for ...... randomized controlled trials.
@nl
prefLabel
Colony-stimulating factors for ...... randomized controlled trials.
@ast
Colony-stimulating factors for ...... randomized controlled trials.
@en
Colony-stimulating factors for ...... randomized controlled trials.
@nl
P2093
P921
P356
P1476
Colony-stimulating factors for ...... randomized controlled trials.
@en
P2093
Aldemar A Castro
Gary H Lyman
Luciana G O Clark
Otavio A C Clark
P304
P356
10.1200/JCO.2005.05.645
P407
P577
2005-06-01T00:00:00Z